Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Munich – page 67

1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munich at a glance
1 191
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 191 trials in Munich

Open in trial search

Plasma cell myeloma

Not recruiting

Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:University Medical Center Hamburg-Eppendorf

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of Durvalumab and Tremelimumab with Y-90 SIRT for Patients with Intermediate Stage Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study of RLY-4008 for Patients with Cholangiocarcinoma and Other Advanced Solid Tumors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RLY-4008
  • Sponsor:Elevar Therapeutics Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of Emavusertib for Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Emavusertib
  • Sponsor:Curis Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Influenza

Not recruiting

Study of mRNA-1010 Influenza Vaccine Compared to Standard Flu Vaccine in Adults 50 Years and Older

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:CX-037231
  • Sponsor:Moderna Inc.

Study on the Effects of TAK-341 for Patients with Multiple System Atrophy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Saline
  • Sponsor:Takeda Development Center Americas Inc.

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AB-1002
  • Sponsor:Askbio Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Munich

What the registry says about research in the country

01 Oncology and Hematologic Malignancies

In München, clinical trials in oncology and blood cancers focus on improving survival, controlling relapse, and refining treatment strategies for a wide range of cancers.

  • Acute myeloid leukemia and myelodysplastic syndrome
  • Breast cancer, prostate cancer, colorectal cancer, and metastatic gastrointestinal cancers
  • Glioblastoma, hepatocellular carcinoma, and renal cell carcinoma
  • Neuroblastoma, rhabdomyosarcoma, and other rare pediatric cancers

These studies are testing new combinations and comparative approaches to strengthen cancer control and better support patients with advanced or hard-to-treat disease.

02 Cardiovascular Disease

Trials in cardiovascular medicine are examining ways to lower major events, improve post-procedure care, and optimize long-term protection in high-risk patients.

  • Atherosclerotic cardiovascular disease and hyperlipidemia
  • Atrial fibrillation after coronary intervention
  • Metabolic and cardiovascular risk in type 2 diabetes
  • Stroke prevention and recovery after acute ischemic stroke

Much of this work aims to improve treatment effectiveness while reducing serious cardiovascular complications.

03 Pulmonary and Respiratory Diseases

Respiratory research in this city is broad, with studies centered on chronic lung disease, inflammation, and treatment options for people with difficult-to-control symptoms.

  • Chronic obstructive pulmonary disease and exacerbation prevention
  • Asthma, including severe eosinophilic and uncontrolled forms
  • Pulmonary arterial hypertension and related pulmonary vascular disease
  • Chronic cough, bronchiectasis, and idiopathic pulmonary fibrosis

These trials are mainly evaluating whether new therapies can improve breathing, symptom control, and long-term lung outcomes.

04 Neurology and Stroke

Neurological research spans emergency stroke care, chronic neurodegenerative disorders, and therapies aimed at preserving daily function and quality of life.

  • Acute ischemic stroke and reperfusion outcomes
  • Amyotrophic lateral sclerosis
  • Alzheimer's disease and mild cognitive impairment
  • Chronic pain syndromes linked to neuropathy and back pain

Research here is exploring better acute treatments, symptom relief, and disease-modifying approaches for progressive neurological conditions.

05 Immunology, Dermatology, and Lupus

Several studies address immune-mediated diseases, including skin disorders and systemic inflammatory conditions, with the goal of improving symptom control and reducing flare burden.

  • Atopic dermatitis
  • Cutaneous lupus erythematosus
  • Psoriatic arthritis
  • Immune system diseases more broadly

These trials are assessing whether newer targeted treatments can provide better and more durable relief for inflammatory disease.

06 Metabolic and Nutritional Disorders

Research in metabolic disease focuses on diabetes control, obesity management, and reduction of long-term cardiometabolic risk.

  • Type 1 diabetes and prevention of progression
  • Type 2 diabetes with high cardiovascular risk
  • Obesity and overweight
  • Weight management and related metabolic complications

The overall aim is to test therapies that may improve glucose control, support weight loss, and lower future complications.

07 Ophthalmology

Eye disease trials are looking at ways to protect vision and slow progression in conditions that can lead to irreversible damage.

  • Geographic atrophy secondary to age-related macular degeneration
  • Ocular treatment safety and long-term tolerability
  • Retinal disease and vision preservation

These studies are designed to improve treatment options for patients facing progressive vision loss.

08 Infectious Diseases and Vaccines

Clinical research in infectious disease includes both prevention and treatment, with attention to viral infection and serious respiratory illness.

  • Cytomegalovirus infection
  • Influenza
  • Respiratory tract infection
  • Vaccine development and immune response

These trials aim to strengthen prevention strategies and improve outcomes in infections that can place a heavy burden on patients and healthcare systems.

09 Kidney, Urologic, and Male Health

Studies in urology and kidney disease address both cancer and transplant-related care, along with advanced prostate cancer.

  • Metastatic hormone-sensitive prostate cancer
  • Renal tumors in children and adults
  • Living donor kidney transplantation
  • Male urogenital diseases more broadly

Research in this area is focused on improving treatment effectiveness, organ outcomes, and long-term patient safety.

10 Musculoskeletal and Pain Conditions

Trials here cover musculoskeletal disease and persistent pain, seeking better ways to relieve symptoms that often limit mobility and daily activity.

  • Osteoarthritis
  • Chronic back pain
  • Neuropathic pain
  • Chronic pain linked to nerve injury or diabetes

The main goal is to evaluate therapies that may provide stronger and more lasting pain relief.

11 Rare and Pediatric Diseases

Several studies in München address rare diseases and childhood cancers, where new treatment approaches are especially important.

  • Neuroblastoma and rhabdomyosarcoma
  • Pediatric renal tumors
  • Ewing sarcoma
  • Myelodysplastic and leukemia disorders in children

These trials are testing ways to improve outcomes for young patients with aggressive or recurrent disease.

12 Allergy, Pulmonary Inflammation, and Immune Processes

Some studies bridge allergy, inflammation, and respiratory disease, reflecting the role of immune pathways in chronic symptoms.

  • Severe eosinophilic asthma
  • Chronic obstructive pulmonary disease with inflammatory features
  • Immune system processes
  • Type 2 inflammation in respiratory disease

These trials are evaluating targeted treatments that may better control inflammation and reduce flare-ups.

13 General Internal Medicine and Multisystem Research

A portion of the trial portfolio does not fit neatly into one specialty, reflecting broad research across overlapping medical conditions and complex patient groups.

  • Pathological conditions, signs, and symptoms
  • Multiple comorbid disease states
  • Mixed cardiovascular-metabolic risk
  • Supportive and comparative treatment research

These studies often aim to improve overall treatment benefit, safety, and real-world applicability across different patient populations.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.